Hi all —

I’m testing a sharper paid-format idea for PDUFA Pulse and wanted to send the first version to this list before I do anything with it publicly.

The idea is simple: not another FDA calendar, but a weekly catalyst grid with the extra columns that matter:

  • approval / CRL / delay split

  • main FDA risk type

  • CRL fixability

  • cash-risk flag

  • setup classification

  • what to watch next

  • calibration after events resolve

Below is a V1 preview.

This is still an editorial/risk-read product, not investment advice, stock calls, or buy/sell/hold recommendations. The goal is to make FDA catalyst setups easier to compare quickly.

My question:

Would this be useful enough as a paid Monday add-on to PDUFA Pulse?

I’m thinking about a low founding price if there’s enough interest — likely something in the range of $79/year or $9/month for early subscribers.

Just reply with one of these if you have a second:

  1. Yes, I’d consider paying for this

  2. Useful, but not paid

  3. Not useful / too much

  4. Useful, but I’d change ______

Thanks — this kind of feedback will help decide whether I keep building it.

-Richard

FDA Catalyst Intelligence · Pro · Free Preview
PDUFA Pulse PRO
WEDNESDAY · JUN 24, 2026  ·  HORIZON: NEXT 60 DAYS  ·  FREE PREVIEW
FIRST ISSUE — NO PRIOR GRID SUPPLIED
PoA = probability-of-approval band, qualitative base-bucket only (no numeric base-rate table supplied) plus source-backed modifiers. Directional, not FDA guidance. Scenario estimates are editorial catalyst-risk views, not investment advice or buy/sell/hold recommendations.
► The Frame · Jun 29 – Aug 22
“MANUFACTURING IS THE CLOCK”

A dense late-June stack opens the board — UNCY and LNTH on Jun 29, VRDN on Jun 30. The recurring near-term pattern is not data quality, it is CMC / facility. UNCY, LNTH, and Orca-T are not mainly “bad data” setups; the paid read is whether manufacturing, facility, or CMC review can still block an otherwise plausible package.

CAPR is the highest-ambiguity row: the CRL was lifted and review resumed, but a prior effectiveness-related CRL plus CBER cell-therapy discretion makes this a recovery setup, not a clean resubmission. VERA and CELC are pathway-risk rows — Priority Review, accelerated approval, and RTOR shorten the clock but do not remove label, safety, surrogate, or postmarketing risk. Calibration is anchored by ACHV (CMC-only CRL) and the GSK/Spero Utebzi recovery.

 
► Core Grid · Live FDA Decision Board
Date Ticker Drug / indication · event PoA · A/C/D
Mon Jun 29 UNCY Oxylanthanum carbonate / hyperphosphatemia in CKD dialysis · NDA Class 2 resubmission
Prior-CRL recovery · risk: CMC/facility		 65–75%
70/20/10
Mon Jun 29 LNTH LNTH-2501 / SSTR+ NET PET imaging · NDA decision after 3-month extension
Manufacturing-review extension · risk: CMC		 68–78%
72/16/12
Tue Jun 30 VRDN Veligrotug / thyroid eye disease · BLA, Priority Review
Priority-review BLA · risk: safety/labeling		 72–82%
77/15/8
Mon Jul 06 Orca Bio Orca-T / hematologic malignancies · BLA after major amendment (private)
CBER / major-amendment setup · risk: CMC/cell therapy		 58–70%
64/24/12
Tue Jul 07 VERA Atacicept / IgA nephropathy · BLA, accelerated approval
Accelerated-approval setup · risk: efficacy/surrogate/label		 62–74%
68/22/10
Fri Jul 17 CELC Gedatolisib / HR+/HER2-, PIK3CA-WT advanced breast cancer · NDA, Priority Review / RTOR
RTOR oncology setup · risk: safety/label		 68–78%
73/18/9
Sat Aug 22 CAPR Deramiocel / DMD cardiomyopathy · BLA Class 2 resubmission
Prior-CRL recovery · risk: efficacy/data package/CBER		 48–60%
52/35/13
Split = approve / CRL / delay. PoA bands are qualitative (base-bucket only). Decisions can resolve on or before the listed date.
 
► Basis / Pro Columns
UNCY · base bucket: Class 2 resubmission; prior CMC/facility CRL

Up: resubmission accepted; issue appears nonclinical.  Down: facility/compliance confirmation still binding; prior CRL recovery remains CMC/facility-dependent.

CRL fix: High Cash: Unknown Anchor: microcap / thinly covered Conf: Data Med / Inf Med
Watch: facility status; launch financing  ·  Source: company PR; SEC filing
LNTH · base bucket: first-cycle NDA; manufacturing-review extension

Up: company says extension not tied to efficacy/safety.  Down: FDA still reviewing manufacturing information.

CRL fix: N/A (CMC-limited) Cash: Low Anchor: well-covered commercial radiopharma Conf: Data High / Inf Med
Watch: manufacturing language at decision  ·  Source: company PR
VRDN · base bucket: first-cycle BLA; Priority Review

Up: Breakthrough designation; Phase 3 support.  Down: TED safety/label differentiation remains the decision point.

CRL fix: N/A Cash: Unknown Anchor: small/mid-cap launch setup Conf: Data High / Inf Med
Watch: safety language; TED label scope  ·  Source: company PR
Orca Bio · Orca-T · base bucket: CBER cell-therapy BLA; major amendment

Up: FDA did not request additional clinical data.  Down: updated CMC package classified as major amendment; cell-therapy manufacturing discretion.

CRL fix: Medium Cash: Unknown Anchor: private company Conf: Data High / Inf Med
Watch: CMC closure; label scope  ·  Source: company PR
VERA · base bucket: accelerated-approval BLA

Up: Priority Review; FDA-aligned proteinuria path; eGFR analysis pulled forward.  Down: surrogate / AA discretion; PMR / full-approval sequencing.

CRL fix: N/A Cash: Unknown Anchor: mid-cap kidney launch setup Conf: Data High / Inf Med
Watch: AA label; PMR language  ·  Source: company PR
CELC · base bucket: first-cycle oncology NDA; RTOR

Up: Priority Review, RTOR, Breakthrough Therapy, Fast Track.  Down: first-cycle oncology safety and line/biomarker label risk.

CRL fix: N/A Cash: Unknown Anchor: small/mid-cap oncology Conf: Data High / Inf Med
Watch: line of therapy; biomarker label  ·  Source: company PR
CAPR · base bucket: Class 2 resubmission; CBER cell therapy; prior CRL

Up: CRL lifted; review resumed; FDA has not identified potential review issues to date.  Down: prior CRL touched effectiveness; first-in-class cell therapy; FDA discretion high.

CRL fix: Medium Cash: Unknown Anchor: microcap / thinly covered Conf: Data High / Inf Med
Watch: labeling dialogue; HOPE-3 adequacy  ·  Source: company PR; Q1 update
 
► Top Setup Notes

First issue: no week-over-week changes yet.

UNCY / LNTH / Orca-T — CMC is the pattern
Not mainly “bad data” setups. The paid read is whether manufacturing, facility, or CMC review can still block an otherwise plausible package.
CAPR — highest-ambiguity row
The CRL was lifted and review resumed, but a prior effectiveness-related CRL plus CBER cell-therapy discretion makes this a recovery setup, not a clean resubmission.
VERA / CELC — pathway-risk rows
Priority Review, accelerated approval, and RTOR shorten the clock, but do not remove label, safety, surrogate, or postmarketing risk.
 
► Setup Complication
!
CMC / MANUFACTURING BOTTLENECKS CAN DECIDE “CLINICALLY CLEAN” REVIEWS
Disclosed fact: LNTH’s extension was tied to additional manufacturing information, not efficacy or safety. Orca-T’s extension followed updated CMC information classified as a major amendment, with no additional clinical data requested. ACHV’s recent CRL cited third-party manufacturing and labeling issues, with no clinical efficacy or safety deficiencies.

Why it matters: for retail catalyst reads, “no clinical deficiency” is not the same as “approval.” CMC / facility risk can still turn an apparently de-risked setup into a resubmission cycle.

Source: company PRs; FDA/company CRL disclosure

Setup Mispricing Flag: none this cycle — no named claimant with a specific, retrievable claim passed the source gate.

 
► Reviewed, Not Elevated
· ARQT / ZORYVE (Jun 29) — source-backed pediatric label expansion, but mostly high-PoA approved-drug expansion. Useful in the free calendar; limited Pro edge unless label/safety wording surprises.
· IONS / TRYNGOLZA (Jun 30) — source-backed Priority Review sNDA. Narrow paid edge: pancreatitis-risk language and label breadth, not core approvability.
· MRNA / MFLUSIVA (Aug 5) — positive VRBPAC vote makes it important, but large-cap / well-covered. Better as an AdCom-to-label watch unless final language sets a reusable vaccine-review precedent.
· BIIB / Leqembi IQLIK (Aug 24) — just outside the 60-day board and heavily covered. Carry into next issue if the device/label-extension angle becomes useful.
· NUVL / zidesamtinib (Sep 18) — outside 60-day horizon. Add to 90-day Pro board as a priority-review NDA / label-data setup.
 
► Resolved Events / Calibration
ACHV / cytisinicline · retro classification CRL
Third-party facility + unfinished labeling; no efficacy/safety deficiencies. High-fixability CRL, but approval still delayed — reinforces that CMC/facility risk deserves its own scenario bucket.
GSK / Spero — Utebzi · retro classification Approved
First oral carbapenem for adults with cUTI. Prior-CRL path resolved in approval after the PIVOT-PO package — useful precedent for resubmission recovery when the new clinical package directly answers the prior deficiency.
MRNA / MFLUSIVA · retro classification AdCom 9–0
VRBPAC voted 9–0 positive. AdCom moved risk from benefit-risk uncertainty toward final label / PMR / age-split execution. Not a final approval yet.
Sanofi / Tzield — peds Stage 3 T1D · retro classification Approved (AA)
Label-expansion outcome; useful for AA pediatric precedent, but no prior grid estimate to score.

One week of retro classifications is not a track record. Live calibration starts with this issue.

 
► Data Gaps
–Numeric base-rate table not supplied. PoA ranges use qualitative base buckets plus source-backed modifiers.
–Market anchors incomplete. Options-implied moves and analyst consensus not pulled; anchor limited to coverage / size / cash context.
–Cash risk incomplete. Several cash-risk fields stay Unknown until latest 10-Q / runway language is pulled.
–UNCY date requires final check. Acceptance PR and later company materials should be reconciled before publication.
Beta Question
Which Pro element is most useful — base bucket, adjustment logic, split, CRL fixability, cash risk, market anchor, setup, or watch item?

Editorial catalyst-risk views · Not investment advice · No buy/sell/hold recommendations · Biotech carries risk of total loss

Keep Reading

© 2026 PDUFA Pulse.
beehiivPowered by beehiiv